Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.
Also Read: AbbVie’s Parkinson’s Disease Therapy Hits FDA Roadblock.
The immunology portfolio generated $6.97 billion in sales, up 2.3% on a reported basis or 3.5% on an operational basis.
Oncology product sales were $1.63 billion, up 10.5% or 12.2% on an operational basis.
Neuroscience revenues reached $2.16 billion, up 14.7% on a reported basis or 15.2% on an operational basis.
Citing BMO Capital Markets analyst Reuters noted that the strong results show “the command AbbVie has over its commercial business and their impressive ability to guide through” the loss of exclusivity for Humira.
Guidance: AbbVie raised its 2024 adjusted EPS guidance from $10.61-$10.81 to $10.71-$10.91 versus consensus of $10.78, which includes an unfavorable impact of $0.60/share related to acquired IPR&D and milestones expense.
In the company conference call, AbbVie announced it is discontinuing further development of the experimental Alzheimer’s drug ABBV-916 as a standalone antibody.
Price Action: ABBV stock is down 5.14% at $185.26 at the last check on Thursday.
Read Next:
Photo via Shutterstock
Posted In: ABBV